Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.
2.

A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema.

Stolk J, Broekman W, Mauad T, Zwaginga JJ, Roelofs H, Fibbe WE, Oostendorp J, Bajema I, Versteegh MI, Taube C, Hiemstra PS.

QJM. 2016 May;109(5):331-6. doi: 10.1093/qjmed/hcw001. Epub 2016 Jan 27.

3.

Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.

van Poelgeest MI, Welters MJ, Vermeij R, Stynenbosch LF, Loof NM, Berends-van der Meer DM, Löwik MJ, Hamming IL, van Esch EM, Hellebrekers BW, van Beurden M, Schreuder HW, Kagie MJ, Trimbos JB, Fathers LM, Daemen T, Hollema H, Valentijn AR, Oostendorp J, Oude Elberink JH, Fleuren GJ, Bosse T, Kenter GG, Stijnen T, Nijman HW, Melief CJ, van der Burg SH.

Clin Cancer Res. 2016 May 15;22(10):2342-50. doi: 10.1158/1078-0432.CCR-15-2594. Epub 2016 Jan 26.

4.

TNF-α and IL-1β-activated human mesenchymal stromal cells increase airway epithelial wound healing in vitro via activation of the epidermal growth factor receptor.

Broekman W, Amatngalim GD, de Mooij-Eijk Y, Oostendorp J, Roelofs H, Taube C, Stolk J, Hiemstra PS.

Respir Res. 2016 Jan 11;17:3. doi: 10.1186/s12931-015-0316-1.

5.

Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma.

Talebian Yazdi M, Loof NM, Franken KL, Taube C, Oostendorp J, Hiemstra PS, Welters MJ, van der Burg SH.

Cancer Immunol Immunother. 2015 Sep;64(9):1109-21. doi: 10.1007/s00262-015-1716-2. Epub 2015 May 30.

6.

CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.

Rosalia RA, Cruz LJ, van Duikeren S, Tromp AT, Silva AL, Jiskoot W, de Gruijl T, Löwik C, Oostendorp J, van der Burg SH, Ossendorp F.

Biomaterials. 2015 Feb;40:88-97. doi: 10.1016/j.biomaterials.2014.10.053. Epub 2014 Nov 26.

PMID:
25465442
7.

Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T; FIRST Trial Team.

N Engl J Med. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551.

8.

Singing can enhance episodic memory functioning in elderly people with Alzheimer's disease.

Oostendorp JC, Montel SR.

J Am Geriatr Soc. 2014 May;62(5):982-3. doi: 10.1111/jgs.12731. No abstract available.

PMID:
24828931
9.

The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study.

de Vos van Steenwijk PJ, van Poelgeest MI, Ramwadhdoebe TH, Löwik MJ, Berends-van der Meer DM, van der Minne CE, Loof NM, Stynenbosch LF, Fathers LM, Valentijn AR, Oostendorp J, Osse EM, Fleuren GJ, Nooij L, Kagie MJ, Hellebrekers BW, Melief CJ, Welters MJ, van der Burg SH, Kenter GG.

Cancer Immunol Immunother. 2014 Feb;63(2):147-60. Epub 2013 Nov 15.

PMID:
24233343
10.

Development of a nose cream containing the synthetic antimicrobial peptide P60.4Ac for eradication of methicillin-resistant Staphylococcus aureus carriage.

Göblyös A, Schimmel KJ, Valentijn AR, Fathers LM, Cordfunke RA, Chan HL, Oostendorp J, Nibbering PH, Drijfhout JW, Hiemstra PS, Hartigh JD.

J Pharm Sci. 2013 Oct;102(10):3539-44. doi: 10.1002/jps.23695. Epub 2013 Aug 17.

PMID:
23955373
11.

Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation.

Rosalia RA, Quakkelaar ED, Redeker A, Khan S, Camps M, Drijfhout JW, Silva AL, Jiskoot W, van Hall T, van Veelen PA, Janssen G, Franken K, Cruz LJ, Tromp A, Oostendorp J, van der Burg SH, Ossendorp F, Melief CJ.

Eur J Immunol. 2013 Oct;43(10):2554-65. doi: 10.1002/eji.201343324. Epub 2013 Aug 5.

12.

Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles.

Rosalia RA, Silva AL, Camps M, Allam A, Jiskoot W, van der Burg SH, Ossendorp F, Oostendorp J.

Cancer Immunol Immunother. 2013 Jul;62(7):1161-73. doi: 10.1007/s00262-013-1411-0. Epub 2013 Apr 24.

PMID:
23613147
13.

HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.

van Poelgeest MI, Welters MJ, van Esch EM, Stynenbosch LF, Kerpershoek G, van Persijn van Meerten EL, van den Hende M, Löwik MJ, Berends-van der Meer DM, Fathers LM, Valentijn AR, Oostendorp J, Fleuren GJ, Melief CJ, Kenter GG, van der Burg SH.

J Transl Med. 2013 Apr 4;11:88. doi: 10.1186/1479-5876-11-88.

14.

Optimization of encapsulation of a synthetic long peptide in PLGA nanoparticles: low-burst release is crucial for efficient CD8(+) T cell activation.

Silva AL, Rosalia RA, Sazak A, Carstens MG, Ossendorp F, Oostendorp J, Jiskoot W.

Eur J Pharm Biopharm. 2013 Apr;83(3):338-45. doi: 10.1016/j.ejpb.2012.11.006. Epub 2012 Nov 29.

PMID:
23201055
15.

Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: a phase I/II clinical trial.

Zeestraten EC, Speetjens FM, Welters MJ, Saadatmand S, Stynenbosch LF, Jongen R, Kapiteijn E, Gelderblom H, Nijman HW, Valentijn AR, Oostendorp J, Fathers LM, Drijfhout JW, van de Velde CJ, Kuppen PJ, van der Burg SH, Melief CJ.

Int J Cancer. 2013 Apr 1;132(7):1581-91. doi: 10.1002/ijc.27819. Epub 2012 Nov 21.

16.

A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions.

de Vos van Steenwijk PJ, Ramwadhdoebe TH, Löwik MJ, van der Minne CE, Berends-van der Meer DM, Fathers LM, Valentijn AR, Oostendorp J, Fleuren GJ, Hellebrekers BW, Welters MJ, van Poelgeest MI, Melief CJ, Kenter GG, van der Burg SH.

Cancer Immunol Immunother. 2012 Sep;61(9):1485-92. doi: 10.1007/s00262-012-1292-7. Epub 2012 Jun 9.

17.

Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study.

Vermeij R, Leffers N, Hoogeboom BN, Hamming IL, Wolf R, Reyners AK, Molmans BH, Hollema H, Bart J, Drijfhout JW, Oostendorp J, van der Zee AG, Melief CJ, van der Burg SH, Daemen T, Nijman HW.

Int J Cancer. 2012 Sep 1;131(5):E670-80. doi: 10.1002/ijc.27388. Epub 2012 Jan 31.

18.

Evaluation of immunological cross-reactivity between clade A9 high-risk human papillomavirus types on the basis of E6-Specific CD4+ memory T cell responses.

van den Hende M, Redeker A, Kwappenberg KM, Franken KL, Drijfhout JW, Oostendorp J, Valentijn AR, Fathers LM, Welters MJ, Melief CJ, Kenter GG, van der Burg SH, Offringa R.

J Infect Dis. 2010 Oct 15;202(8):1200-11. doi: 10.1086/656367.

PMID:
20822453
19.

Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses.

Welters MJ, Kenter GG, de Vos van Steenwijk PJ, Löwik MJ, Berends-van der Meer DM, Essahsah F, Stynenbosch LF, Vloon AP, Ramwadhdoebe TH, Piersma SJ, van der Hulst JM, Valentijn AR, Fathers LM, Drijfhout JW, Franken KL, Oostendorp J, Fleuren GJ, Melief CJ, van der Burg SH.

Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11895-9. doi: 10.1073/pnas.1006500107. Epub 2010 Jun 14.

20.

Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia.

Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Essahsah F, Fathers LM, Offringa R, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, van der Burg SH, Melief CJ.

N Engl J Med. 2009 Nov 5;361(19):1838-47. doi: 10.1056/NEJMoa0810097.

21.

Immunization with a P53 synthetic long peptide vaccine induces P53-specific immune responses in ovarian cancer patients, a phase II trial.

Leffers N, Lambeck AJ, Gooden MJ, Hoogeboom BN, Wolf R, Hamming IE, Hepkema BG, Willemse PH, Molmans BH, Hollema H, Drijfhout JW, Sluiter WJ, Valentijn AR, Fathers LM, Oostendorp J, van der Zee AG, Melief CJ, van der Burg SH, Daemen T, Nijman HW.

Int J Cancer. 2009 Nov 1;125(9):2104-13. doi: 10.1002/ijc.24597.

22.

Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer.

Speetjens FM, Kuppen PJ, Welters MJ, Essahsah F, Voet van den Brink AM, Lantrua MG, Valentijn AR, Oostendorp J, Fathers LM, Nijman HW, Drijfhout JW, van de Velde CJ, Melief CJ, van der Burg SH.

Clin Cancer Res. 2009 Feb 1;15(3):1086-95. doi: 10.1158/1078-0432.CCR-08-2227.

23.

Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.

Welters MJ, Kenter GG, Piersma SJ, Vloon AP, Löwik MJ, Berends-van der Meer DM, Drijfhout JW, Valentijn AR, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, Melief CJ, van der Burg SH.

Clin Cancer Res. 2008 Jan 1;14(1):178-87. doi: 10.1158/1078-0432.CCR-07-1880.

24.

Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.

Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, Drijfhout JW, Wafelman AR, Oostendorp J, Fleuren GJ, Offringa R, van der Burg SH, Melief CJ.

Clin Cancer Res. 2008 Jan 1;14(1):169-77. doi: 10.1158/1078-0432.CCR-07-1881.

25.

Differential desensitization of homozygous haplotypes of the beta2-adrenergic receptor in lymphocytes.

Oostendorp J, Postma DS, Volders H, Jongepier H, Kauffman HF, Boezen HM, Meyers DA, Bleecker ER, Nelemans SA, Zaagsma J, Meurs H.

Am J Respir Crit Care Med. 2005 Aug 1;172(3):322-8. Epub 2005 May 5.

26.

Exposure to TARC alters beta2-adrenergic receptor signaling in human peripheral blood T lymphocytes.

Heijink IH, Vellenga E, Oostendorp J, de Monchy JG, Postma DS, Kauffman HF.

Am J Physiol Lung Cell Mol Physiol. 2005 Jul;289(1):L53-9. Epub 2005 Mar 4.

27.

Modulation of beta2- and beta3-adrenoceptor-mediated relaxation of rat oesophagus smooth muscle by protein kinase C.

Oostendorp J, Obels PP, Terpstra AR, Nelemans SA, Zaagsma J.

Eur J Pharmacol. 2004 Jul 8;495(1):75-81.

PMID:
15219823
28.

Localization and enhanced mRNA expression of the orphan chemokine receptor L-CCR in the lung in a murine model of ovalbumin-induced airway inflammation.

Oostendorp J, Hylkema MN, Luinge M, Geerlings M, Meurs H, Timens W, Zaagsma J, Postma DS, Boddeke HW, Biber K.

J Histochem Cytochem. 2004 Mar;52(3):401-10.

PMID:
14966207
29.

Cloning, pharmacological characterization, and polymorphism screening of the guinea pig beta(2)-adrenoceptor.

Oostendorp J, Meurs H, Adriaan Nelemans S, Zaagsma J, Kauffman HF, Postma DS, Boddeke HW, Biber K.

Eur J Pharmacol. 2002 Dec 13;457(1):1-10.

PMID:
12460637
30.

Contribution of beta-adrenoceptor subtypes to relaxation of colon and oesophagus and pacemaker activity of ureter in wildtype and beta(3)-adrenoceptor knockout mice.

Oostendorp J, Preitner F, Moffatt J, Jimenez M, Giacobino JP, Molenaar P, Kaumann AJ.

Br J Pharmacol. 2000 Jun;130(4):747-58.

32.

Physiologically based toxicokinetic modeling of 1,3-butadiene lung metabolism in mice becomes more important at low doses.

Evelo CT, Oostendorp JG, ten Berge WF, Borm PJ.

Environ Health Perspect. 1993 Nov;101(6):496-502.

33.

Quantitative determination of antibiotics by automated six-point parallel-line agar diffusion assay.

Detmar DA, van Hemert KH, Malherbe R, Oostendorp JG.

Antonie Van Leeuwenhoek. 1974;40(4):610-1. No abstract available.

PMID:
4549477
34.

A quantitative microbiological determination of 6-aminopenicillanic acid.

Oostendorp JG.

Antonie Van Leeuwenhoek. 1972;38(2):201-6. No abstract available.

PMID:
4338004
35.

Thin-layer chromatography on sephadex for the identification of antibiotics.

Zuidweg MH, Oostendorp JG, Bos CJ.

J Chromatogr. 1969 Jul 22;42(4):552-4. No abstract available.

PMID:
4979585

Supplemental Content

Loading ...
Support Center